Analyst Mohit Bansal of Wells Fargo maintained a Buy rating on Mineralys Therapeutics, Inc. (MLYS – Research Report), with a price target of $26.00.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Mohit Bansal has given his Buy rating due to a combination of factors that highlight the potential growth and strategic developments of Mineralys Therapeutics, Inc. The company is poised to release significant data from its Explore-CKD and Launch-HTN trials, which could serve as near-term catalysts. The upcoming presentation of detailed Launch-HTN data at a major conference and the anticipated regulatory update on NDA submission further bolster confidence in the company’s trajectory.
Additionally, Mineralys’ ongoing OSA trial presents an opportunity to expand the application of lorundrostat beyond hypertension, potentially improving outcomes for patients with sleep apnea. The company’s robust cash position supports these initiatives, and management’s strategic focus on partnerships could enhance the commercialization of lorundrostat both domestically and internationally. These factors collectively underpin the Buy rating, reflecting optimism about the company’s ability to achieve meaningful clinical and commercial milestones.
MLYS’s price has also changed moderately for the past six months – from $13.380 to $15.010, which is a 12.18% increase.